BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32735012)

  • 1. Drug Resistance Mutations Among South African Children Living With HIV on WHO-recommended ART Regimens.
    Hackett S; Teasdale CA; Pals S; Muttiti A; Mogashoa M; Chang J; Zeh C; Ramos A; Rivadeneira ED; DeVos J; Sleeman K; Abrams EJ
    Clin Infect Dis; 2021 Oct; 73(7):e2217-e2225. PubMed ID: 32735012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
    Avi R; Pauskar M; Karki T; Kallas E; Jõgeda EL; Margus T; Huik K; Lutsar I
    J Med Virol; 2016 Mar; 88(3):448-54. PubMed ID: 26291050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
    Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
    PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
    Ayitewala A; Kyeyune F; Ainembabazi P; Nabulime E; Kato CD; Nankya I
    AIDS Res Ther; 2020 Jan; 17(1):2. PubMed ID: 32005262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
    Van Zyl GU; Liu TF; Claassen M; Engelbrecht S; de Oliveira T; Preiser W; Wood NT; Travers S; Shafer RW
    PLoS One; 2013; 8(6):e67188. PubMed ID: 23840622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon.
    Nzengui-Nzengui GF; Mourembou G; M'boyis-Kamdem H; Kombila-Koumavor AC; Ndjoyi-Mbiguino A
    BMC Infect Dis; 2024 Mar; 24(1):316. PubMed ID: 38486188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.
    Technau KG; Lazarus E; Kuhn L; Abrams EJ; Sorour G; Strehlau R; Reubenson G; Davies MA; Coovadia A
    Pediatr Infect Dis J; 2013 Aug; 32(8):851-5. PubMed ID: 23860481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
    Kamya MR; Mayanja-Kizza H; Kambugu A; Bakeera-Kitaka S; Semitala F; Mwebaze-Songa P; Castelnuovo B; Schaefer P; Spacek LA; Gasasira AF; Katabira E; Colebunders R; Quinn TC; Ronald A; Thomas DL; Kekitiinwa A;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):187-93. PubMed ID: 17693883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.
    Sylla M; Dolo O; Maiga AI; Traore FT; Coulibaly YA; Togo J; Fofana DB; Dicko-Traore F; Doumbia S; Orsega S; Diallo S; Murphy RL; Calvez V; Marcelin AG
    Arch Pediatr; 2019 Jul; 26(5):254-258. PubMed ID: 31307909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon.
    Liégeois F; Vella C; Eymard-Duvernay S; Sica J; Makosso L; Mouinga-Ondémé A; Mongo AD; Boué V; Butel C; Peeters M; Gonzalez JP; Delaporte E; Rouet F
    J Int AIDS Soc; 2012 Nov; 15(2):17985. PubMed ID: 23199801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries.
    Crowell TA; Danboise B; Parikh A; Esber A; Dear N; Coakley P; Kasembeli A; Maswai J; Khamadi S; Bahemana E; Iroezindu M; Kiweewa F; Owuoth J; Freeman J; Jagodzinski LL; Malia JA; Eller LA; Tovanabutra S; Peel SA; Ake JA; Polyak CS;
    Clin Infect Dis; 2021 Oct; 73(7):e2311-e2322. PubMed ID: 32785695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.
    Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M
    J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
    Clumeck N; Mwamba C; Kabeya K; Matanda S; Vaira D; Necsoi C; Kadiebwe D; Delforge M; Kasamba E; Milolo C; Ilunga J; Kapend L
    AIDS; 2014 May; 28(8):1143-53. PubMed ID: 25028911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.